Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

tremelimumab

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tremelimumab

38 trials tracked of tremelimumab: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 18 citations.

38Trials tracked

1Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 1 Phase 2 30 Phase 1 5 Other / NA 2

Show 32 more trials

Phase 2 Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Completed
Phase 2 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Completed
Phase 2 Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Completed
Phase 2 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin Completed
Phase 2 Tremelimumab With Chemoembolization or Ablation for Liver Cancer Completed
Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
Phase 2 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Completed
Phase 2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Completed
Phase 2 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed
Phase 2 Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Completed
Phase 2 GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed
Phase 2 Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Completed
Phase 2 Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer Completed
Phase 2 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Completed
Phase 2 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Completed
Phase 2 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach Completed
Phase 2 Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Completed
Phase 2 MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer Completed
Phase 2 Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Completed
Phase 2 A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Completed
Phase 2 CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Completed
Phase 2 A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer Completed
Phase 2 Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer Completed
Phase 2 Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer Completed
Phase 2 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Completed
Phase 1 A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab Completed
Phase 1 Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients Completed
Phase 1 Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery Completed
Phase 1 Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer Completed
Phase 1 A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors Completed
N/A Brain Irradiation and Tremelimumab in Metastatic Breast Cancer Completed
N/A Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.